Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study

BACKGROUND: Hyperphosphatemia is common in chronic kidney disease (CKD) and associated with mortality and morbidity. We aimed to evaluate the dose-dependent efficacy and safety of PA21 (sucroferric oxyhydroxide), an iron-based phosphate binder, in Japanese hemodialysis patients with hyperphosphatemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Koiwa, Fumihiko, Terao, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486467/
https://www.ncbi.nlm.nih.gov/pubmed/27389681
http://dx.doi.org/10.1007/s10157-016-1299-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486467/
https://www.ncbi.nlm.nih.gov/pubmed/27389681
http://dx.doi.org/10.1007/s10157-016-1299-z

Ejemplares similares